Panthera and Rutherford partner to create oncology trial network

Panthera and Rutherford Health have announced to launch innovative oncology clinical trial network. Credit: Rutherford Health plc.

Panthera and Rutherford Health have formed a strategic collaboration to create a network of advanced clinical trial sites for developing new cancer treatments.

Free Whitepaper

Revolutionising chromatography and clarification in biopharma production

Biopharma companies are under constant pressure to improve productivity, maintain product purity, and cut costs. Yet this is far from straightforward. Process intensification is desired, but there are barriers to making processes more efficient.

Chromatography and clarification play vital parts in biopharma manufacturing, yet there is room for improvement in processes to eliminate inefficiencies and increase yield.

Single-stage clarification technologies, such as 3M™ Harvest RC Chromatographic Clarifier, could play a vital role in this journey, by simplifying what would otherwise be a time-consuming and complex

clarification train.

This document delves into the history of chromatography and clarification, addresses problems, proposes solutions, and offers a glimpse into what the future may look like after a revolution in biopharma production processing. Download to learn more.

By 3M

The information you provide are used by 3M Company and its group companies, in accordance with 3M Global Privacy Policy as shown at 3M.com/privacy, for the purpose of (i) following up with you via email or telephone on any event sponsored / co-organized / participated by 3M, your questions, interests or requests; (ii) making materials available to you; and (iii) inviting you to future events; and (iv) based on your consent, sending you newsletters, advertisements, surveys and information about promotions and offers of 3M Company and its group companies via email. Please use the Intake form to object. EMEA residents: please read 3M privacy notice, opt in language & exact information on 3M data controller relevant to your location here

By downloading this Whitepaper, you acknowledge that we may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our privacy policy for more information about our services, how we may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Under the partnership, known as Panthera@theRutherford, Panthera’s clinical trials managing expertise will be combined with Rutherford ’s UK network of advanced centres and team of key oncologists.

Rutherford’s independent network currently comprises four cancer treatment centres. These centres are located in Newport, Reading, Bedlington and Liverpool.

Rutherford’s network will draw patients from all over the UK. It provides the Pharma and contract research organisations (CROs) access to patients through over 170 ‘referring oncologists’.

Each of the Rutherford Cancer Centres has state-of-the-art diagnostics including MRI, CT, and proton beam therapy, as well as offering chemotherapy, Immunotherapy and radiotherapy treatments.

These facilities, combined with leading oncologists, Panthera’s clinical trial professionals, and an experienced cancer care team, ensure that patients receive the highest possible standard of care.

Rutherford Health PLC CEO Mike Moran said: “We are delighted to partner with Panthera to provide professional cancer research in our centres. By collaborating with Panthera and our team of oncologists, we will be at the forefront of research into innovative therapies and we’ll be able offer more opportunities to patients and access to life-saving treatments.”

Each Rutherford Cancer Centre has advanced diagnostics including MRI, CT, and proton beam therapy treatments. These centres also offer chemotherapy, immunotherapy, and radiotherapy treatments.